In furtherance to the intimation given by the Company on 22nd September, 2023 with respect to making any investments or acquisition by way of subscription, purchase or otherwise, the securities of other body corporates by the company up to 40,00,00,000 over and above the limits available under Section 186 of the Companies Act, 2013. Pharmaids Pharmaceuticals has informed that the Board of Directors at their meeting held on January 06, 2024 have approved purchase of up to 36,75,959 Equity Shares of Adita Bio Sys (Target Company). The Board has also approved the execution of definitive agreements to give effect to the above acquisition. With the said acquisition the Company aims to acquire majority stake in the Target Company through share swap. The details as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in Annexure – A to this letter.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.00 |
| Dr. Reddys Lab | 1224.00 |
| Cipla | 1231.40 |
| Zydus Lifesciences | 931.00 |
| Lupin | 2326.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: